{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+diphtheria+toxoid&page=3",
    "query": {
      "intervention": "Tetanus diphtheria toxoid",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 99,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+diphtheria+toxoid&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+diphtheria+toxoid&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T21:33:25.578Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03207750",
      "title": "This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rotavirus Infection",
        "Rotavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevenar 13",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 1280,
      "start_date": "2017-09-14",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207750"
    },
    {
      "nct_id": "NCT00263692",
      "title": "Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diphtheria",
        "Acellular Pertussis",
        "Tetanus"
      ],
      "interventions": [
        {
          "name": "Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 401,
      "start_date": "2002-11",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2016-09-15",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 15,
      "location_summary": "Jonesboro, Arkansas • Fountain Valley, California • Oakland, California + 12 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00263692"
    },
    {
      "nct_id": "NCT03334305",
      "title": "Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "High Grade Glioma"
      ],
      "interventions": [
        {
          "name": "TTRNA-DC vaccines with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose-intensified TMZ",
          "type": "DRUG"
        },
        {
          "name": "Autologous Hematopoietic Stem cells (HSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TTRNA-xALT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 18,
      "start_date": "2018-08-27",
      "completion_date": "2025-03-20",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03334305"
    },
    {
      "nct_id": "NCT03615404",
      "title": "Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Malignant Glioma",
        "Medulloblastoma Recurrent",
        "Pediatric Glioblastoma Multiforme",
        "Pediatric Brain Tumor, Recurrent",
        "Pediatric Brain Tumor"
      ],
      "interventions": [
        {
          "name": "CMV-DCs with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td (tetanus toxoid)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gary Archer Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "0 Years to 35 Years"
      },
      "enrollment_count": 11,
      "start_date": "2018-10-05",
      "completion_date": "2020-07-02",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03615404"
    },
    {
      "nct_id": "NCT06254326",
      "title": "ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Oligodendroglioma",
        "Progressive Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "TTRNA-DC vaccines with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Hematopoietic Stem cells (HSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TTRNA-xALT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-09-19",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-11-17",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06254326"
    },
    {
      "nct_id": "NCT02096263",
      "title": "Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Poliomyelitis",
        "Diphtheria",
        "Haemophilus Influenzae Type b",
        "Tetanus",
        "Acellular Pertussis",
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Infanrix hexa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ActHIB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pentacel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Infanrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 585,
      "start_date": "2014-04-16",
      "completion_date": "2015-11-13",
      "has_results": true,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 43,
      "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096263"
    },
    {
      "nct_id": "NCT03063736",
      "title": "Entolimod, an Adjuvant for Vaccine Augmentation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "Entolimod",
          "type": "DRUG"
        },
        {
          "name": "Td Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "18 Years to 40 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2017-12-08",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-09-01",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03063736"
    },
    {
      "nct_id": "NCT03673462",
      "title": "Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy Volunteers (Meningococcal Infection)"
      ],
      "interventions": [
        {
          "name": "Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, Mumps, and Rubella Virus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella Virus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 2797,
      "start_date": "2018-09-17",
      "completion_date": "2023-03-16",
      "has_results": true,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03673462"
    },
    {
      "nct_id": "NCT01711645",
      "title": "Tdap Vaccine in Post-Partum Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diphtheria",
        "Pertussis",
        "Tetanus"
      ],
      "interventions": [
        {
          "name": "Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 55,
      "start_date": "2012-10-26",
      "completion_date": "2015-08-28",
      "has_results": true,
      "last_update_posted_date": "2017-05-05",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01711645"
    },
    {
      "nct_id": "NCT00536120",
      "title": "The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BG00002 (natalizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "keyhole limpet hemocyanin (KLH)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tetanus diphtheria toxoid vaccine (Td)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-01",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2017-02-15",
      "last_synced_at": "2026-11-19T21:33:25.578Z",
      "location_count": 10,
      "location_summary": "Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Patchogue",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00536120"
    }
  ]
}